NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
iOnctura
University of Southern California
TILT Biotherapeutics Ltd.
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
EMD Serono